Ibarra PC, Kelly GJ, Fernández CMA

Language: Spanish
References: 6
Page: 153-158
PDF size: 133.84 Kb.

ABSTRACT

Diagnosis of bronchogenic carcinoma is usually made in the late stages of the disease when surgical treatment is no longer feasible; thus it is clear that a high index of suspicion is mandatory to diagnose the disease in its early stages. We describe the clinical and radiographic syndromes that can lead to early suspicion of the disease, and imaging and invasive procedures confirmatory of the diagnosis and clinical stage, as well as type of treatment to be offered according to the International Staging System for Lung Cancer.

REFERENCES

1. Ibarra-Pérez C, Kelly-García J. Cáncer broncogénico de células no pequeñas. En: Oncología del tórax. México: UNAM, PUIS, Coordinación de la Vinculación, Miguel Ángel Porrúa; 1999. p. 31-91.

2. Schottenfeld D. Etiology and epidemiology of lung cancer. En: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD, editors. Lung cancer. Principles and practice. Philadelphia: Lippincott Williams and Wilkins; 2000. p. 367-388.

3. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717.

4. Ibarra-Pérez C, Kelly-García J. Valoración y prepa-ración preoperatorios, cuidados y complicaciones postoperatorios en cirugía de tórax. En: Oncología del tórax. México: UNAM, PUIS, Coordinación de la Vinculación, Miguel Ángel Porrúa; 1999. p. 233-265.

5. Martínez FJ, Iannettoni M, Paine II R. Medical evaluation and management of the lung cancer patient prior to surgery, radiation or chemotherapy. En: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD, editors. Lung cancer. Principles and practice. Philadelphia: Lippincott Williams and Wilkins; 2000. p. 649-681.

6. Pisters KAM, Ginsberg RJ. On behalf of the Bimodality Lung Oncology Team (BLOT) phase II trial of induction paclitaxel and carbopiatin (PC) in early stage (T2 N0, TI-2Nl) and selected T3N0-1 non-small cell lung cancer (NSCLC). Proc ASCO 1998; 17(Abst. 1738):451a.